Category Archives: discovery

EMA Announces Drug Development Modeling and Simulation Workshop

EMA Announces Drug Development Modeling and Simulation Workshop

Full Text Here

The objective of the workshop is to discuss the role and scope of modelling and simulation in drug-development both from the developer’s and the regulator’s perspectives. Registration by invitation only. Registration open until 14/10/2011. Places limited.



For Assistance with Product Development Planning Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Open Access Therapeutic Drug Targets Database Launched

Open Access Therapeutic Drug Targets Database Launched

Direct Access Here

A comprehensive database of therapeutic drug targets extracted from patents or patent applications, Sciclips has launched a unique, comprehensive and publicly accessible database on therapeutic drug targets. This database contains drug targets reported in US patents or US/International patent applications. The drug targets are classified according to specific drug types (e.g. small molecule drugs, protein drugs, antibody drugs, siRNA drugs, miRNA drugs etc.) and disease types. The assays and methods used for characterizing each drug targets are listed as well. In addition to this, all the drug targets are linked to PubMed, Google Scholar, GeneBank, UniProt, USPTO database, WO(PCT) database and Google Patents.

SciClips’ therapeutic drug target database is a valuable resource for biomedical and pharmaceutical researchers around the world. This one-of-a-kind database will help scientists to search for drug target/s of their choice from a huge database containing -4000 drug targets which are linked to their respective disease/s types. The database helps the researchers with the ability to search original patent/s or patent application/s linked to the particular drug target to get more information.

Click Here for Drug Development Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Open Access Therapeutic Drug Targets Database Launched

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Open Access Therapeutic Drug Targets Database Launched

Drug Development – Logic Models of Pathway Biology

As part of our drug development consultancy we often investigate alternative indications for technologies, we progress through the therapeutic pathway and think about where this drug/biological may have an effect be that positive or negative. Having just read an interesting article in Drug Discovery Today (Vol 13 (9/10) May 2008) by Watterson, Marshall and Ghazal. The article titles “logic models of pathway biology” looks at complex living systems and how logic can be used to determine how a drug will interact with the complex biologic pathways.

They describe computational models that comb the pathways for the upstream interactions that control downstream behaviour, allowing them to identify lead candidates for therapeutic treatments. They take the kind of literature based approach we follow to the next level studying proteins, genes and gene products.

Biological pathways can comprise one or more of the following:

  • Metabolic pathways
  • Molecular interactions
  • Gene regulatory networks
  • Signalling pathways

Whilst the researchers hear focus on Boolean Logic and computer modeling we hold that a good review of possible effects and pathways can be tackled using literature searches and scientific hypothesis. I would propose that any drug or biological agent should undergo a similar scrutiny to find new opportunities and highlight potential issues.

Where we look at biological systems they magnify the process, the target the same, an understanding of how a system operates.  It is an interesting article that is well worth reading.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 Drug Development   Logic Models of Pathway Biology

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.